HIV-1 Entry and Membrane Fusion Inhibitors. PMID: 33922579
How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design. PMID: 28422787
The env gene variability is not directly related to the high cytopathogenicity of an HIV1 variant. PMID: 2371777
Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability. PMID: 35692162
Sequencing the Biology of Entry: The Retroviral env Gene. PMID: 28688086
HIV-1 replication. PMID: 12465460
HIV-1 pseudoviruses constructed in China regulatory laboratory. PMID: 31859609
Soluble Prefusion Closed DS-SOSIP.664-Env Trimers of Diverse HIV-1 Strains. PMID: 29212041
RRE-dependent HIV-1 Env RNA effects on Gag protein expression, assembly and release. PMID: 24971705
Reducing HIV-1 env gene CpG frequency increases the replication capacity of the HXB2 virus strain. PMID: 35041864
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. PMID: 21762802
Construction and Characterization of HIV-1 env-Pseudoviruses of the Recombinant Form CRF63_02A and Subtype A6. PMID: 35501651
Immunogenicity of HIV-1 envelope glycoprotein oligomers. PMID: 20048701
Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators. PMID: 34627310
HIV1 cytopathogenicity-genetic difference between direct cytotoxic and fusogenic effect. PMID: 1733106
Vpr Enhances HIV-1 Env Processing and Virion Infectivity in Macrophages by Modulating TET2-Dependent IFITM3 Expression. PMID: 31431548
Structure of the transmembrane domain of HIV-1 envelope glycoprotein. PMID: 27868386
Association of envelope-specific B-cell differentiation and viral selective pressure signatures in HIV-1 CRF01_AE infection. PMID: 35848590
HIV-1 Envelope FRETted Over by Antibodies. PMID: 31194935
Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. PMID: 27992602
[Revisiting HIV-1 assembly]. PMID: 18198110
AIDS virus envelope spike structure. PMID: 17395457
Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. PMID: 24937308
Small Molecule HIV-1 Attachment Inhibitors: Discovery, Mode of Action and Structural Basis of Inhibition. PMID: 34066522
Phylogenetics of HIV-1 subtype G env: Greater complexity and older origins than previously reported. PMID: 26190450
Dolutegravir inhibits HIV-1 Env evolution in primary human cells. PMID: 25849829
Recent advance in the structural analysis of HIV-1 envelope protein. PMID: 25921945
Defining HIV-1 Envelope N-Glycan Microdomains through Site-Specific Heterogeneity Profiles. PMID: 30305355
Variable infectivity and conserved engagement in cell-to-cell viral transfer by HIV-1 Env from Clade B transmitted founder clones. PMID: 30415130
HIV-1 Envelope Glycoprotein at the Interface of Host Restriction and Virus Evasion. PMID: 30935048
Use of dual recombinant vaccinia virus vectors to assay viral glycoprotein-mediated fusion with transfection-resistant primary cell targets. PMID: 15114024
Genotypic characterization of CRF01_AE env genes derived from human immunodeficiency virus type 1-infected patients residing in central Thailand. PMID: 19108694
Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time. PMID: 35372102
Functional and structural segregation of overlapping helices in HIV-1. PMID: 35511220
Reverted HIV-1 Mutants in CD4+ T-Cells Reveal Critical Residues in the Polar Region of Viral Envelope Glycoprotein. PMID: 34935422
High throughput functional analysis of HIV-1 env genes without cloning. PMID: 17416428
Genotypic tests for determining coreceptor usage of HIV-1. PMID: 21288812
Variations in Env at amino acids 328 and 330 affect HIV-1 replicative fitness and entry inhibitor sensitivity. PMID: 33862046
CpG Frequency in the 5' Third of the env Gene Determines Sensitivity of Primary HIV-1 Strains to the Zinc-Finger Antiviral Protein. PMID: 31937644
Validation of an automated system for aliquoting of HIV-1 Env-pseudotyped virus stocks. PMID: 29300769
HIV Rev Assembly on the Rev Response Element (RRE): A Structural Perspective. PMID: 26075509
Centralized HIV-1 envelope immunogens and neutralizing antibodies. PMID: 18045113
HIV1 V3 loop hypermutability is enhanced by the guanine usage bias in the part of env gene coding for it. PMID: 20109155
Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine. PMID: 22509350
Syncytin-1 nonfusogenic activities modulate inflammation and contribute to preeclampsia pathogenesis. PMID: 35536515
Origins and evolutionary consequences of ancient endogenous retroviruses. PMID: 30962577
HIV Env on Lockdown. PMID: 29902434
Mechanisms for Env glycoprotein acquisition by retroviruses. PMID: 21247353
Probing Structural Variation and Dynamics in the HIV-1 Env Fusion Glycoprotein. PMID: 29268688
HIV-1 Envelope Conformation, Allostery, and Dynamics. PMID: 34067073
A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody. PMID: 29749030
The Interplay between HIV-1 Gag Binding to the Plasma Membrane and Env Incorporation. PMID: 32429351
The role of matrix in HIV-1 envelope glycoprotein incorporation. PMID: 24933691
Editorial: The HIV/SIV Envelope Protein: From Structure To Function To Host Evasion. PMID: 29708481
Structural principles controlling HIV envelope glycosylation. PMID: 28363124
Cell fusion induced senescence. PMID: 24859630
Polyadenylation of Friend murine leukemia virus env-mRNA is affected by its splicing. PMID: 24935657
HIV-1 envelope glycoprotein structure. PMID: 23602427
Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. PMID: 28202756
HIV-1 assembly, budding, and maturation. PMID: 22762019
Cell fusions in mammals. PMID: 18351375
An efficiently cleaved HIV-1 clade C Env selectively binds to neutralizing antibodies. PMID: 25822521
Metastable HIV-1 Surface Protein Env Sensitizes Cell Membranes to Transformation and Poration by Dual-Acting Virucidal Entry Inhibitors. PMID: 31942789
Reconstitution of Fusion-Competent Human Placental Fusogen Syncytin-2. PMID: 35596004
Antibody epitope exposure and neutralization of HIV-1. PMID: 21128886
Virus and cell fusion mechanisms. PMID: 25000995
Confronting the fissions and fusions of human fertilization. PMID: 24771117
Cryo-EM Structure of Full-length HIV-1 Env Bound With the Fab of Antibody PG16. PMID: 31931014
Glycosylation profiling to evaluate glycoprotein immunogens against HIV-1. PMID: 28870097
Synthesis and assembly of chimeric human immunodeficiency virus gag pseudovirions. PMID: 8957668
HIV-1 Env trimer opens through an asymmetric intermediate in which individual protomers adopt distinct conformations. PMID: 29561264
Retroviral host range extension is coupled with Env-activating mutations resulting in receptor-independent entry. PMID: 28607078
Truncation of cytoplasmic tail of EIAV Env increases the pathogenic necrosis. PMID: 18294721
Comment to "Syncytin expression in human placental trophoblast". PMID: 35691202
ALV-J GP37 molecular analysis reveals novel virus-adapted sites and three tyrosine-based Env species. PMID: 25849207
Functions of HIV envelope glycans. PMID: 8160267
Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response., PMID:40461490
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines., PMID:40438096
Immunoinformatic-driven design and evaluation of multi-epitope mRNA vaccine targeting HIV-1 gp120., PMID:40433366
A broad antibody with enhanced HIV-1 neutralization via bispecific antibody-mediated prepositioning., PMID:40383778
Conformational trajectory of the HIV-1 fusion peptide during CD4-induced envelope opening., PMID:40382314
Distinct region-specific neutralization profiles of contemporary HIV-1 clade C against best-in-class broadly neutralizing antibodies., PMID:40377318
Vaccination of nonhuman primates elicits a broadly neutralizing antibody lineage targeting a quaternary epitope on the HIV-1 Env trimer., PMID:40339576
Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains., PMID:40261015
Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes., PMID:40239787
Distinctive Membrane Accommodation Traits Underpinning the Neutralization Activity of HIV-1 Antibody against MPER., PMID:40202993
Safety, pharmacokinetics, and biological activity of CD4-mimetic BNM-III-170 in SHIV-infected rhesus macaques., PMID:40192306
Ab initio prediction of specific phospholipid complexes and membrane association of HIV-1 MPER antibodies by multi-scale simulations., PMID:40192122
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns., PMID:40178906
Molecular parameters governing antibody FcγR signaling and effector functions in the context of HIV envelope., PMID:40158219
The membrane-proximal external region of human immunodeficiency virus (HIV-1) envelope glycoprotein trimers in A18-lipid nanodiscs., PMID:40089599
Afucosylated broadly neutralizing antibodies targeting the HIV envelope elicit enhanced NK-cell-mediated cytotoxicity against HIV-infected CD4+ T-cell and macrophage targets., PMID:40086815
Adeno-associated viral delivery of Env-specific antibodies prevents SIV rebound after discontinuing antiretroviral therapy., PMID:40020046
Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge., PMID:40007032
Versatile Features of an Antibody Mimetic Peptide and Its Variants., PMID:39962901
NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption., PMID:39953264
Cysteines shape antibody battles for HIV-1 Env., PMID:39947129
Activation of CXCR3+ Tfh cells and B cells in lymph nodes during acute HIV-1 infection correlates with HIV-specific antibody development., PMID:39932316
Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development., PMID:39909038
High HIV-1 viremia and low anti-Env antibody responses are associated with delayed treatment response to fostemsavir in highly treatment-experienced individuals., PMID:39889907
Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity., PMID:39836706
Current methods for detecting and assessing HIV-1 antibody resistance., PMID:39835119
Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage., PMID:39826122
Anti-immune complex antibodies are elicited during repeated immunization with HIV Env immunogens., PMID:39823319
Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance., PMID:39817771
Experimental medicine study with stabilised native-like HIV-1 Env immunogens drives long-term antibody responses, but lacks neutralising breadth., PMID:39753033
Mechanisms of sterilizing immunity provided by an HIV-1 neutralizing antibody against mucosal infection., PMID:39724193
[Virus-Like Particles Carrying HIV-1 Env with a Modulated Glycan Composition]., PMID:39709569
A multidonor class of highly glycan-dependent HIV-1 gp120-gp41 interface-targeting broadly neutralizing antibodies., PMID:39675002
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell Lines., PMID:39671174
Genetic Characteristics of the Env Regions in HIV-1-Infected Subjects in Baoding City, Hebei Province, China., PMID:39648424
Vaccine-elicited and naturally elicited antibodies differ in their recognition of the HIV-1 fusion peptide., PMID:39611147
Comparative Analysis of IMT-P8 and LDP12 Cell-Penetrating Peptides in Increasing Immunostimulatory Properties of HIV-1 Nef-MPER-V3 Antigen., PMID:39558498
Inducible cell lines producing replication-defective human immunodeficiency virus particles containing envelope glycoproteins stabilized in a pretriggered conformation., PMID:39508605
Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies., PMID:39489734
Potent broadly neutralizing antibodies mediate efficient antibody-dependent phagocytosis of HIV-infected cells., PMID:39466835
Generation of a Nonbilayer Lipid Nanoenvironment after Epitope Binding Potentiates Neutralizing HIV-1 MPER Antibody., PMID:39446590
Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity., PMID:39380992
CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies., PMID:39373535
Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes., PMID:39361585
Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions., PMID:39343065
AI-based IsAb2.0 for antibody design., PMID:39285513
Conjugation of anti-HIV gp41 monoclonal antibody to a drug capable of targeting resting lymphocytes produces an effective cytotoxic anti-HIV immunoconjugate., PMID:39283123
Immunization of cows with HIV envelope trimers generates broadly neutralizing antibodies to the V2-apex from the ultralong CDRH3 repertoire., PMID:39250525
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity., PMID:39248460
Conformations of membrane human immunodeficiency virus (HIV-1) envelope glycoproteins solubilized in Amphipol A18 lipid-nanodiscs., PMID:39248459
For research use only. Not for human or drug use.
